Blog

Bispecific ADCs advance oncology. Biointron shows how dual-targeted antibody-drug conjugates improve precision, efficacy, and patient outcomes in cancer treatment.

Learn how transgenic animals are transforming antibody discovery by generating fully human antibodies for biomedical research, diagnostics, and drug development.

Antibodies defend health by neutralizing pathogens, aiding phagocytosis, and activating complement. Biointron explains these vital functions in immunity and therapy.

Analytical tools define antibody quality. Biointron applies SPR, BLI, and mass spectrometry to deliver precise characterization and support therapeutic success.

Explore the role of anti-idiotype antibodies and critical reagents in therapeutic antibody development, ensuring specificity, potency, and safety in drug testing.

The 4th Fc-Mediated Function Summit in Boston showcased Fc engineering advances. Biointron reports key insights driving next-generation antibody therapeutics.

Antibody-drug conjugates unite precision with potency. Biointron outlines how ADCs combine antibodies with cytotoxic drugs to deliver targeted cancer therapies.

AACR 2024 in San Diego spotlighted breakthroughs in cancer research. Biointron shares highlights on antibody therapeutics, discovery platforms, and translational science.

Learn about Fab, F(ab')2, and Fc antibody fragments—how they are generated, their roles in antigen targeting, and their evolving applications in biomedical research and therapy.

Antibody generation is tightly regulated. Biointron examines mechanisms that control immune responses and ensure balance between protection and tolerance.

From hybridomas to recombinant platforms, antibody production has evolved. Biointron reveals ten insights into methods that ensure reliable supply and scientific progress.

Bispecific antibodies are transforming medicine. Biointron highlights their design, therapeutic applications, and development pathways for next-generation therapies.